Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04047251 · ClinicalTrials.gov registry record · Phase 1

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma

A Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma, sponsored by Fujifilm Pharmaceuticals U.S.A..

Active
Registry status
Phase 1
Development phase
96
Enrollment target
7
Study locations

NCT04047251 is a Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma that is active but no longer recruiting, run by Fujifilm Pharmaceuticals U.S.A.. The registered enrollment target is 96 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (52% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04047251, a Phase 1 study of Advanced Solid Tumors and Merkel Cell Carcinoma, is active but no longer recruiting, sponsored by Fujifilm Pharmaceuticals U.S.A..

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
96 participants
Enrollment target
7
Study locations

Study Summary

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

Conditions Studied

Advanced Solid Tumors Merkel Cell Carcinoma

Interventions

  • DRUG FF-10850 Topotecan Liposome Injection

Study Locations (7)

Arizona

  • HonorHealth - Scottsdale

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Massachusetts

  • Dana Farber Cancer Institute (DFCI) - Boston

New York

  • Icahn School of Medicine at Mount Sinai - New York

Ohio

  • Ohio State University Wexner Medical Center - Columbus

Texas

  • MD Anderson Cancer Center - Houston

Wisconsin

  • University of Wisconsin Clinical Science Center - Madison

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2019-11-14
Est. Completion 2026-07
Phase Phase 1

Sponsor

Fujifilm Pharmaceuticals U.S.A.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04047251

The ClinicalTrials.gov registry entry for NCT04047251 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (52% lower). The listed sponsor is Fujifilm Pharmaceuticals U.S.A., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which FF-10850 Topotecan Liposome Injection is the first listed.

NCT04047251 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Arizona, Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04047251 about?

NCT04047251 is a clinical study titled "A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma". To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma

What is the current status of trial NCT04047251?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2019-11-14. Estimated completion is 2026-07.

What conditions does trial NCT04047251 study?

This clinical trial studies the following conditions: Advanced Solid Tumors, Merkel Cell Carcinoma.

What interventions are being tested in trial NCT04047251?

The interventions under investigation include: FF-10850 Topotecan Liposome Injection (DRUG).

Who is sponsoring clinical trial NCT04047251?

This trial is sponsored by Fujifilm Pharmaceuticals U.S.A., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04047251 being conducted?

This trial has 7 study locations across Arizona, Colorado, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Merkel Cell Carcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.